Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer
- Author
- REIGNER, Bruno1 2 ; WATANABE, Toru3 ; KIMURA, Mitsunori12 ; MONKHOUSE, Jayne13 ; YORULMAZ, Cahit1 ; WEIDEKAMM, Erhard1 ; GRANGE, Susan1 ; SCHÜLLER, Johannes4 ; LUCRAFT, Helen5 ; SASAKI, Yasutsuna6 ; BRIDGEWATER, John7 ; SAEKI, Toshiaki8 ; MCALEER, James9 ; KURANAMI, Masaru10 ; POOLE, Christopher11
[1] F. Hoffmann-La Roche Ltd., Basel, Switzerland
[2] Medical Science, Clinical Pharmacology. PDMP, 15/1.036, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
[3] National Cancer Hospital, Tokyo, Japan
[4] Hospital Rudolfstiftung, Vienna, Austria
[5] Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
[6] National Cancer Center East Hospital, Kashiwa, Japan
[7] University College London, London, United Kingdom
[8] National Shikoku Cancer Center, Matsuyama, Japan
[9] Belfast City Hospital, Belfast, United Kingdom
[10] Kitasako University School of Medicine, Sagamihara, Japan
[11] Cancer Research UK, Birmingham, United Kingdom
[12] Nippon Roche, Tokyo, Japan
[13] Roche Products, Welwyu, United Kingdom - Source
Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 3, pp 193-201, 9 p ; ref : 37 ref
- CODEN
- CCPHDZ
- ISSN
- 0344-5704
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, Berlin
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Capecitabine Caucasian Ethnicity Japanese Pharmacokinetics
- Keyword (fr)
- Anticancéreux Capécitabine Caucasoïde Chimiothérapie Femelle Fluoropyrimidine dérivé Glande mammaire Homme Japonais Pharmacocinétique Plasma sanguin Traitement Tumeur maligne Voie orale Cytidine dérivé Glande mammaire pathologie
- Keyword (en)
- Antineoplastic agent Capecitabine Caucasoid Chemotherapy Female Fluoropyrimidine derivatives Mammary gland Human Japanese Pharmacokinetics Blood plasma Treatment Malignant tumor Oral administration Mammary gland diseases
- Keyword (es)
- Anticanceroso Capecitabina Caucásico Quimioterapia Hembra Fluoropirimidina derivado Glándula mamaria Hombre Japonés Farmacocinética Plasma sanguíneo Tratamiento Tumor maligno Vía oral Glándula mamaria patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 15105841
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00280-003-0642-8 
https://dx.doi.org/10.1007/s00280-003-0642-8
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-003-0642-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"193\";s:8:\"\u0000*\u0000epage\";s:3:\"201\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"REIGNER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Bruno\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:14:\"WATANABE, Toru\";i:1;s:17:\"KIMURA, Mitsunori\";i:2;s:16:\"MONKHOUSE, Jayne\";i:3;s:15:\"YORULMAZ, Cahit\";i:4;s:17:\"WEIDEKAMM, Erhard\";i:5;s:13:\"GRANGE, Susan\";i:6;s:19:\"SCH\u00dcLLER, Johannes\";i:7;s:14:\"LUCRAFT, Helen\";i:8;s:17:\"SASAKI, Yasutsuna\";i:9;s:17:\"BRIDGEWATER, John\";i:10;s:15:\"SAEKI, Toshiaki\";i:11;s:14:\"MCALEER, James\";i:12;s:16:\"KURANAMI, Masaru\";i:13;s:18:\"POOLE, Christopher\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-003-0642-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"193\";s:8:\"\u0000*\u0000epage\";s:3:\"201\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"REIGNER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Bruno\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:14:\"WATANABE, Toru\";i:1;s:17:\"KIMURA, Mitsunori\";i:2;s:16:\"MONKHOUSE, Jayne\";i:3;s:15:\"YORULMAZ, Cahit\";i:4;s:17:\"WEIDEKAMM, Erhard\";i:5;s:13:\"GRANGE, Susan\";i:6;s:19:\"SCH\u00dcLLER, Johannes\";i:7;s:14:\"LUCRAFT, Helen\";i:8;s:17:\"SASAKI, Yasutsuna\";i:9;s:17:\"BRIDGEWATER, John\";i:10;s:15:\"SAEKI, Toshiaki\";i:11;s:14:\"MCALEER, James\";i:12;s:16:\"KURANAMI, Masaru\";i:13;s:18:\"POOLE, Christopher\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-003-0642-8\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-003-0642-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"193\";s:8:\"\u0000*\u0000epage\";s:3:\"201\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"REIGNER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Bruno\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:14:\"WATANABE, Toru\";i:1;s:17:\"KIMURA, Mitsunori\";i:2;s:16:\"MONKHOUSE, Jayne\";i:3;s:15:\"YORULMAZ, Cahit\";i:4;s:17:\"WEIDEKAMM, Erhard\";i:5;s:13:\"GRANGE, Susan\";i:6;s:19:\"SCH\u00dcLLER, Johannes\";i:7;s:14:\"LUCRAFT, Helen\";i:8;s:17:\"SASAKI, Yasutsuna\";i:9;s:17:\"BRIDGEWATER, John\";i:10;s:15:\"SAEKI, Toshiaki\";i:11;s:14:\"MCALEER, James\";i:12;s:16:\"KURANAMI, Masaru\";i:13;s:18:\"POOLE, Christopher\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-003-0642-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"193\";s:8:\"\u0000*\u0000epage\";s:3:\"201\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"REIGNER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Bruno\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:14:\"WATANABE, Toru\";i:1;s:17:\"KIMURA, Mitsunori\";i:2;s:16:\"MONKHOUSE, Jayne\";i:3;s:15:\"YORULMAZ, Cahit\";i:4;s:17:\"WEIDEKAMM, Erhard\";i:5;s:13:\"GRANGE, Susan\";i:6;s:19:\"SCH\u00dcLLER, Johannes\";i:7;s:14:\"LUCRAFT, Helen\";i:8;s:17:\"SASAKI, Yasutsuna\";i:9;s:17:\"BRIDGEWATER, John\";i:10;s:15:\"SAEKI, Toshiaki\";i:11;s:14:\"MCALEER, James\";i:12;s:16:\"KURANAMI, Masaru\";i:13;s:18:\"POOLE, Christopher\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-003-0642-8\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"52\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"193\";s:8:\"\u0000*\u0000epage\";s:3:\"201\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"REIGNER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Bruno\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:14:\"WATANABE, Toru\";i:1;s:17:\"KIMURA, Mitsunori\";i:2;s:16:\"MONKHOUSE, Jayne\";i:3;s:15:\"YORULMAZ, Cahit\";i:4;s:17:\"WEIDEKAMM, Erhard\";i:5;s:13:\"GRANGE, Susan\";i:6;s:19:\"SCH\u00dcLLER, Johannes\";i:7;s:14:\"LUCRAFT, Helen\";i:8;s:17:\"SASAKI, Yasutsuna\";i:9;s:17:\"BRIDGEWATER, John\";i:10;s:15:\"SAEKI, Toshiaki\";i:11;s:14:\"MCALEER, James\";i:12;s:16:\"KURANAMI, Masaru\";i:13;s:18:\"POOLE, Christopher\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:95:\"Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer\";s:8:\"\u0000*\u0000place\";s:6:\"Berlin\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
